Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc is focused on developing IMVT-1402, an FcRn inhibitor aimed at reducing pathogenic IgG antibodies related to autoimmune diseases, highlighting its potential in addressing conditions like Graves' disease (GD). The company's clinical data indicates a sustained reduction in TRAb levels during the off-treatment period and an impressive responder rate of 81%, comparably robust to the active treatment phase. These findings underscore the durability of effect and disease-modifying potential of FcRn blockers, fostering a positive outlook for Immunovant's stock.

Bears say

Immunovant Inc's outlook remains negative due to the ongoing risks associated with persistently high TRAbs levels, which have been linked to increased rates of relapse in patients. The potential complications arising from TRAbs-mediated TSHR activation, including severe inflammation and the risk of optic nerve compression, underline significant clinical challenges that may impede the company's development efforts. Additionally, the focus on a single operating segment raises concerns about the company's ability to diversify its risk profile and effectively manage its reliance on the success of its product candidates.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.